Upon receipt, samples undergo rigorous quality assessment for integrity and microbial biomass. This ensures optimal input for downstream processes, mitigating potential contamination risks.
Intratumoral Microbiota Traceability Analysis Service
Background Service Workflow Advantages Customer Reviews FAQs Contact Us
To address critical challenges in cancer research, such as understanding diverse therapeutic responses and identifying novel therapeutic targets, Creative Biolabs provides a cost-effective intratumoral microbiota traceability analysis service. This service helps you accelerate drug discovery and develop highly specific treatment strategies by elucidating the intricate relationships between intratumoral microbial communities and tumor biology through advanced sequencing and bioinformatics platforms.
Background and Significance
Recent research has unveiled the complex ecosystem within tumors, revealing that intratumoral microbiota are not merely bystanders but active participants influencing cancer initiation, progression, and response to therapy. These microbial communities can modulate the tumor microenvironment, impact immune responses, and affect the efficacy of various cancer treatments, including chemotherapy and immunotherapy. Understanding this intricate interplay is crucial for developing more effective and personalized cancer therapies. While gene therapy focuses on genetic modifications to treat disease, the efficacy of such therapies, especially in oncology, can be significantly influenced by the tumor's biological context, including its microbial inhabitants. Our analysis service provides foundational insights into this context, supporting the development of a new generation of targeted cancer treatments.
Fig.1 Harnessing the power of the intratumoral microbiome to improve cancer therapy.1
Intratumoral Microbiota Traceability Analysis Service at Creative Biolabs
At Creative Biolabs, our intratumoral microbiota traceability analysis service offers comprehensive solutions for characterizing microbial communities within tumor samples. We take advantage of the principle of genomic sequencing and advanced next-generation sequencing (NGS) technologies, coupled with sophisticated bioinformatics analysis, to perform this assay, typically completed within 8 to 12 weeks. This process provides actionable insights for your oncology research and drug development programs, allowing you to expect detailed microbial profiles, identification of key microbial players, and their potential correlations with tumor characteristics and treatment outcomes.
Workflow
Sample Collection & Quality Control
DNA Extraction & Library Preparation
High-quality microbial DNA is meticulously extracted from the tumor samples. Subsequently, 16S rRNA gene (for bacteria/archaea) or ITS (Internal Transcribed Spacer) region (for fungi) libraries are prepared using advanced protocols for targeted sequencing.
High-Throughput Sequencing
Prepared libraries are subjected to next-generation sequencing (NGS) platforms, generating millions of reads to capture the diversity and abundance of microbial populations within the samples.
Bioinformatics Analysis
Raw sequencing data undergoes comprehensive processing, including quality filtering, chimera removal, and operational taxonomic unit (OTU) or amplicon sequence variant (ASV) clustering. Taxonomic assignment is performed to identify specific microbial species and genera.
Statistical & Comparative Analysis
Advanced statistical tools are employed to analyze microbial diversity (alpha and beta diversity), differential abundance, and correlation with provided clinical parameters or experimental groups. This step identifies significant microbial shifts or biomarkers.
Functional Prediction & Pathway Analysis
Leveraging databases and algorithms, we predict the potential functional capabilities of the identified microbial communities and their associated metabolic pathways within the tumor microenvironment.
Our Service Highlights
- Precision Insights: Uncover the exact microbial species and their abundance within tumor tissues.
- Enhanced Drug Discovery: Identify novel therapeutic targets and biomarkers by understanding microbiota-tumor interactions.
- Personalized Medicine: Inform patient stratification and guide treatment selection based on unique intratumoral microbial signatures.
- Robust & Reproducible Data: Benefit from our rigorous quality control and advanced bioinformatics pipelines.
- Cost-Effective Solutions: Obtain high-quality, comprehensive analysis without prohibitive costs.
Customer Reviews
The detailed microbial profiling using Creative Biolabs' service significantly improved our understanding of tumor heterogeneity in colorectal cancer, allowing us to pinpoint specific bacterial populations influencing drug metabolism. This tangible benefit expedited our lead optimization phase.
- 12/2024, Mar** K***
Using Creative Biolabs' Intratumoral Microbiota Traceability Analysis Service in our research has significantly facilitated the identification of novel therapeutic targets. Their comprehensive data reports and insightful bioinformatics analysis are far superior to alternatives we've explored, offering precise and reliable information.
- 09/2024, S. Pat*****
The quality assurance provided by Creative Biolabs for their intratumoral microbiota analysis is exceptional. The clarity of their results and the detailed methodology helped us overcome previous challenges in sample contamination, providing a strong foundation for our ongoing clinical trials. We highly recommend their service.
- 06/2025, J. Fost***
FAQs
Q1: What types of samples can be submitted for Intratumoral Microbiota Traceability Analysis?
A1: We primarily accept tumor tissue samples (fresh frozen, FFPE blocks, or cell pellets from biopsies/resections), relevant clinical data (e.g., diagnosis, treatment history), and control samples (matched normal tissue or healthy donor tissue) for comparative analysis. Discussing your specific sample type and preparation with our team is recommended for optimal results.
Q2: How can understanding intratumoral microbiota benefit my cancer research project?
A2: By characterizing the microbial landscape within tumors, you can gain insights into drug resistance mechanisms, identify novel therapeutic targets (e.g., for microbiota-modulating therapies), stratify patients for personalized treatments, and discover predictive biomarkers for treatment response.
Q3: How does Creative Biolabs ensure the quality and accuracy of the microbiota analysis?
A3: We employ stringent quality control steps, from initial sample assessment and DNA extraction to library preparation and sequencing. Our advanced bioinformatics pipelines are validated to ensure high data fidelity and reproducible, accurate microbial profiling.
Q4: Can Creative Biolabs' service differentiate between intratumoral microbiota and environmental contaminants?
A4: Yes, our advanced bioinformatics protocols incorporate strategies to identify and mitigate environmental contaminants, ensuring that the detected microbial signals are genuinely tumor-associated. We also recommend submitting appropriate control samples for more robust analysis.
Why Choose Creative Biolabs
Creative Biolabs is dedicated to advancing cancer research through cutting-edge scientific services. Our Intratumoral Microbiota Traceability Analysis Service offers unparalleled precision and insight into the complex microbial ecosystems within tumors, empowering you to make groundbreaking discoveries and develop more effective therapies. If you want to get more information, please feel free to reach out to us.
Reference
- Wang, Na et al. "Intratumoral microbiome: implications for immune modulation and innovative therapeutic strategies in cancer." Journal of biomedical science vol. 32,1 23. 19 Feb. 2025. Distributed under Open Access License CC BY 4.0, without modification. DOI: https://doi.org/10.1186/s12929-025-01117-x
Download our brochureLoading case studies...
Online Inquiry